Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Illinois AAT Testing Policy Update | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IllinoisPolicy RPLAB061

    Testing for Alpha-1 Antitrypsin Deficiency

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Illinois Policy RPLAB061 alerts

    Get alerted when Policy RPLAB061 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs reimbursement criteria and coding for laboratory testing used to evaluate alpha-1 antitrypsin deficiency. It applies to providers submitting claims to Blue Cross Blue Shield of Illinois, subject to applicable plan documents and provider contracts.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyTesting for Alpha-1 Antitrypsin Deficiency
    Policy CodePolicy RPLAB061
    Change TypeProcedure code update
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionApply the listed indication and once-per-lifetime frequency criteria before submitting AAT testing for reimbursement.
    SourceLink
    POLICY UPDATE CHANGES

    Procedure codes 82542 and 82789 were removed from the policy's code list.

    The policy references were revised.

    Once per lifetimeTesting frequency
    8Qualifying initial testing situations
    2Current procedure codes
    Not reimbursableUnlisted indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reimbursable and Non-Reimbursable Testing

    Potentially Reimbursable Initial AAT Testing

    Testing may be reimbursable once per lifetime when an individual is suspected of having alpha-1 antitrypsin (AAT) deficiency and all applicable criteria below are met.

    ALL of the following

    • The individual is suspected of having alpha-1 antitrypsin (AAT) deficiency.
    • Testing includes serum quantification of AAT protein and either AAT phenotyping or AAT proteotyping.

      AAT phenotyping should be performed using isoelectric focusing. AAT proteotyping (Pi typing or protease inhibitor typing) for Z and S alleles should be performed using liquid chromatography-tandem mass spectrometry.

    • The testing is performed no more than once per lifetime.
    • ONE of the following indications

      • The individual is symptomatic and 18 years of age or older with emphysema, chronic obstructive pulmonary disease (COPD), or asthma.
      • The individual has unexplained liver disease, such as chronic hepatitis with or without cirrhosis, chronically elevated aminotransferase levels, portal hypertension, or primary liver cancer.
      • The individual has persistent obstruction on pulmonary function tests without identifiable risk factors, such as cigarette smoking or occupational exposure.
      • The individual is 18 years of age or older and has necrotizing panniculitis.
      • The individual is a sibling of an individual with known AAT deficiency.
      • The individual has anti-proteinase three-positive vasculitis (C-ANCA-positive vasculitis).
      • The individual has bronchiectasis without evident etiology.
      • The individual has neonatal cholestasis.

    Follow-Up Phenotyping for Unresolved Suspicion

    Additional phenotyping may be reimbursable when initial testing does not resolve a persistent clinical suspicion of AAT deficiency.

    ALL of the following

    • ONE of the following testing findings

      • Genotype testing is negative for common variants.
      • Results are discordant between AAT serum levels and proteotype.
    • Clinical suspicion of AAT deficiency remains.
    • The additional testing is isoelectric focusing/phenotyping.

    Non-Reimbursable Situations

    Testing for AAT deficiency is not reimbursable when the situation does not meet the reimbursable criteria above.

    All other situations not described in the potentially reimbursable initial testing or follow-up phenotyping criteria are not reimbursable.

    Procedure Codes and Frequency Limits

    Listed procedure codes for alpha-1 antitrypsin testingCPT
    82103Alpha-1-antitrypsin total
    82104Alpha-1-antitrypsin phenotype
    Removed procedure codesCPTNot Covered
    82542Code removed from the policy code list
    82789Code removed from the policy code list
    Testing frequency
    Testing serviceSerum AAT protein quantification and AAT phenotyping or proteotyping
    Frequency limitOnce per lifetime
    Coverage conditionA listed clinical or familial indication for suspected AAT deficiency must be documented

    Claim Submission Requirements

    Documentation Required

    Submit accurate claim documentation and coding

    Submit accurate documentation of the services performed and use valid code combinations from HIPAA-approved code sets. Code claims according to applicable industry-standard coding guidelines, including CPT, HCPCS, ICD-10-CM, ICD-10-PCS, and relevant CMS guidelines.

    Documentation Required

    Provide additional documentation upon request

    Claims are subject to review under benefit coverage terms, provider contract language, medical policies, reimbursement policies, and coding software logic. Provide additional documentation upon request.

    Testing Method Definitions

    AAT phenotyping
    MethodIsoelectric focusing
    Applies toAAT phenotyping
    Policy requirementAAT phenotyping should be performed using isoelectric focusing
    AAT proteotyping
    MethodLiquid chromatography-tandem mass spectrometry
    Applies toAAT proteotyping, including Pityping or protease inhibitor typing
    AllelesZ and S alleles
    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyTesting for Alpha-1 Antitrypsin Deficiency
    Policy CodePolicy RPLAB061
    Change TypeProcedure code update
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionApply the listed indication and once-per-lifetime frequency criteria before submitting AAT testing for reimbursement.
    SourceLink
    On This Page
    Reimbursable and Non-Reimbursable TestingProcedure Codes and Frequency LimitsClaim Submission RequirementsTesting Method Definitions
    Billing Rule

    Apply indication and frequency criteria

    For suspected AAT deficiency, serum AAT protein quantification and AAT phenotyping or proteotyping may be reimbursable once per lifetime only when a listed clinical or familial indication is documented.

    • Symptomatic individual age 18 or older with emphysema, COPD, or asthma
    • Unexplained liver disease
    • Persistent pulmonary-function-test obstruction without identifiable risk factors
    • Individual age 18 or older with necrotizing panniculitis
    • Sibling of an individual with known AAT deficiency
    • Anti-proteinase three-positive (C-ANCA-positive) vasculitis
    • Bronchiectasis without evident etiology
    • Neonatal cholestasis
    Denial Risk

    Avoid non-listed testing indications

    Do not submit alpha-1 antitrypsin deficiency testing for reimbursement when the clinical situation is not described among the policy’s qualifying indications or follow-up testing circumstances. Testing in all other situations is not reimbursable.

    Billing Rule

    Use specified testing methods for unresolved suspicion

    When clinical suspicion of AAT deficiency remains after negative genotype results for common variants or discordant AAT serum levels and proteotype results, use the specified testing methods. Phenotyping should use isoelectric focusing; proteotyping for Z and S alleles should use liquid chromatography-tandem mass spectrometry.